Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CPRXNASDAQ:NBIXNYSE:NVSNASDAQ:PLRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPRXCatalyst Pharmaceuticals$23.46+1.7%$22.96$14.47▼$26.16$2.86B0.71.11 million shs1.34 million shsNBIXNeurocrine Biosciences$121.54+2.2%$106.06$84.23▼$157.98$12.02B0.261.10 million shs2.88 million shsNVSNovartis$111.80+1.1%$110.26$96.06▼$120.92$236.17B0.61.56 million shs1.48 million shsPLRXPliant Therapeutics$1.43$1.51$1.10▼$16.52$87.78M1.431.07 million shs711,838 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPRXCatalyst Pharmaceuticals-5.10%-5.02%-0.04%-1.45%+53.84%NBIXNeurocrine Biosciences+8.36%+10.89%+24.33%-21.35%-16.08%NVSNovartis-2.09%-2.36%+4.67%+0.81%+13.29%PLRXPliant Therapeutics-10.06%-3.38%+6.72%-88.61%-89.63%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCPRXCatalyst Pharmaceuticals4.68 of 5 stars3.62.00.03.92.93.32.5NBIXNeurocrine Biosciences4.9068 of 5 stars4.43.00.02.93.22.53.1NVSNovartis2.4117 of 5 stars2.03.02.50.03.40.01.9PLRXPliant Therapeutics4.1511 of 5 stars4.02.00.04.72.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPRXCatalyst Pharmaceuticals 3.13Buy$32.2937.62% UpsideNBIXNeurocrine Biosciences 2.86Moderate Buy$162.0033.29% UpsideNVSNovartis 2.00Hold$123.3810.35% UpsidePLRXPliant Therapeutics 2.00Hold$13.31830.94% UpsideCurrent Analyst Ratings BreakdownLatest PLRX, NVS, CPRX, and NBIX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2025NBIXNeurocrine BiosciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform5/6/2025NBIXNeurocrine BiosciencesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$137.00 ➝ $145.005/6/2025NBIXNeurocrine BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$160.00 ➝ $154.005/6/2025NBIXNeurocrine BiosciencesUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$137.00 ➝ $152.005/6/2025NBIXNeurocrine BiosciencesBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Perform ➝ Market Perform$96.00 ➝ $115.005/6/2025NBIXNeurocrine BiosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$155.00 ➝ $165.005/6/2025NBIXNeurocrine BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$138.00 ➝ $139.005/6/2025NBIXNeurocrine BiosciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$158.00 ➝ $160.004/28/2025NBIXNeurocrine BiosciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$163.00 ➝ $158.004/24/2025NBIXNeurocrine BiosciencesEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$190.00 ➝ $185.004/15/2025NVSNovartisBNP ParibasSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 5/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPRXCatalyst Pharmaceuticals$491.73M5.82$2.19 per share10.72$3.30 per share7.11NBIXNeurocrine Biosciences$2.36B5.11$3.54 per share34.35$25.97 per share4.68NVSNovartis$53.22B4.44$11.15 per share10.03$21.59 per share5.18PLRXPliant Therapeutics$1.58M55.56N/AN/A$7.91 per share0.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPRXCatalyst Pharmaceuticals$71.41M$1.3119.8811.013.3131.01%40.79%34.87%5/7/2025 (Estimated)NBIXNeurocrine Biosciences$341.30M$3.2936.9418.780.7714.49%13.38%9.73%N/ANVSNovartis$11.94B$6.4019.0112.691.7023.56%37.24%15.85%7/17/2025 (Estimated)PLRXPliant Therapeutics-$161.34M-$3.47N/AN/AN/AN/A-48.91%-41.09%N/ALatest PLRX, NVS, CPRX, and NBIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025CPRXCatalyst Pharmaceuticals$0.53$0.63+$0.10$0.45$130.86 millionN/A5/5/2025Q1 2025NBIXNeurocrine Biosciences$0.70$0.08-$0.62$0.08$587.06 million$572.60 million4/29/2025Q1 2025NVSNovartis$2.12$2.28+$0.16$1.83$12.92 billion$13.23 billion3/3/2025Q4 2024PLRXPliant Therapeutics-$0.99-$0.82+$0.17-$0.82$0.08 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCPRXCatalyst PharmaceuticalsN/AN/AN/AN/AN/ANBIXNeurocrine BiosciencesN/AN/AN/AN/AN/ANVSNovartis$2.592.32%+5.34%40.47%N/APLRXPliant TherapeuticsN/AN/AN/AN/AN/ALatest PLRX, NVS, CPRX, and NBIX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date2/20/2025NVSNovartis$3.86953/12/20253/12/20253/12/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPRXCatalyst PharmaceuticalsN/A5.114.92NBIXNeurocrine BiosciencesN/A3.403.28NVSNovartis0.481.040.84PLRXPliant Therapeutics0.0910.2610.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPRXCatalyst Pharmaceuticals79.22%NBIXNeurocrine Biosciences92.59%NVSNovartis13.12%PLRXPliant Therapeutics97.30%Insider OwnershipCompanyInsider OwnershipCPRXCatalyst Pharmaceuticals10.40%NBIXNeurocrine Biosciences4.30%NVSNovartis0.01%PLRXPliant Therapeutics6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPRXCatalyst Pharmaceuticals80121.96 million106.15 millionOptionableNBIXNeurocrine Biosciences1,20098.94 million95.42 millionOptionableNVSNovartis101,7002.11 billion2.04 billionOptionablePLRXPliant Therapeutics9061.39 million56.96 millionOptionablePLRX, NVS, CPRX, and NBIX HeadlinesRecent News About These CompaniesBarclays PLC Lowers Stock Holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX)May 6 at 3:33 AM | marketbeat.comPliant Therapeutics announces workforce reductionMay 3, 2025 | uk.investing.comPliant Therapeutics Announces Workforce Reduction and Cost Saving Initiatives to Support Late-Stage Clinical TrialsMay 3, 2025 | nasdaq.comPliant Therapeutics (PLRX) Projected to Post Earnings on MondayMay 3, 2025 | americanbankingnews.comBay Area biotech company Pliant Therapeutics slashes staff after losing $655 million in valueMay 2, 2025 | msn.comPliant Axes 45% of Workforce To Save Cash, Support Late-Stage Clinical TrialsMay 2, 2025 | biospace.comPliant Therapeutics cuts workforce by 45% after bexotegrast trial safety woesMay 2, 2025 | fiercebiotech.comPliant Therapeutics Announces Strategic Realignment of Workforce and OperationsMay 1, 2025 | globenewswire.com649,660 Shares in Pliant Therapeutics, Inc. (NASDAQ:PLRX) Purchased by Adage Capital Partners GP L.L.C.May 1, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Sells 200,327 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX)May 1, 2025 | marketbeat.comFirst Light Asset Management LLC Has $22.14 Million Stock Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX)April 30, 2025 | marketbeat.comPliant Therapeutics (PLRX) to Release Quarterly Earnings on MondayApril 30, 2025 | marketbeat.comBrokerages Set Pliant Therapeutics, Inc. (NASDAQ:PLRX) Price Target at $13.31April 30, 2025 | americanbankingnews.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Rating of "Hold" by BrokeragesApril 28, 2025 | marketbeat.comBlue Owl Capital Holdings LP Has $36.47 Million Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX)April 26, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. – PLRXApril 25, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRXApril 24, 2025 | accessnewswire.comSilverarc Capital Management LLC Makes New $17.33 Million Investment in Pliant Therapeutics, Inc. (NASDAQ:PLRX)April 24, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRXApril 23, 2025 | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRXApril 21, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRXApril 21, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePLRX, NVS, CPRX, and NBIX Company DescriptionsCatalyst Pharmaceuticals NASDAQ:CPRX$23.46 +0.40 (+1.73%) Closing price 04:00 PM EasternExtended Trading$23.68 +0.22 (+0.96%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.Neurocrine Biosciences NASDAQ:NBIX$121.54 +2.62 (+2.20%) Closing price 03:59 PM EasternExtended Trading$121.76 +0.22 (+0.18%) As of 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.Novartis NYSE:NVS$111.80 +1.25 (+1.13%) Closing price 03:59 PM EasternExtended Trading$113.74 +1.94 (+1.73%) As of 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.Pliant Therapeutics NASDAQ:PLRX$1.43 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.44 +0.01 (+0.70%) As of 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Disney Stock Jumps on Earnings—Is the Magic Sustainable? AMD Relieves Market Despite Ongoing Share Price Outlook Caution Gold’s Record Run in 2025: Here Are 3 Ways to Ride the Surge What the New Quarter Says About Super Micro Computer's Future Archer Stock Eyes Q1 Earnings After UAE Updates Ford Motor Stock Rises After Earnings, But Momentum May Not Last Broadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx Boost Lemonade Delivers Sweet Results, Price Reversal to Accelerate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
